<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218124</url>
  </required_header>
  <id_info>
    <org_study_id>Remismooth2217</org_study_id>
    <nct_id>NCT03218124</nct_id>
  </id_info>
  <brief_title>Optimal Remifentanil Concentration and Thyroidectomy</brief_title>
  <acronym>ORCO</acronym>
  <official_title>Optimal Effect Site Remifentanil Concentration for Smooth Extubation After Thyroid Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cagliari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at determining the remifentanil effect site concentration suppressing the
      cough at extubation after surgical thyroidectomy, performed under remifentanil/desflurane
      based general anesthesia, expressed as median and 95th percentile effective dose.

      Possible hemodynamic instability, respiratory depression or prolongation of awakening time
      are also sought.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective observational study. Decreasing/increasing remifentanil effect site concentrations (Dixon's up and down model) to obtain cough-free extubation after thyroidectomy</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patient under general anesthesia unaware of the effect site concentration of remifentanil before extubation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cough</measure>
    <time_frame>15 minutes after surgery</time_frame>
    <description>Any episode of sudden and violent abdominal contraction interrupting normal quite spontaneous or assisted ventilation would be accounted as &quot;cough&quot; and defines non-smooth extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics 1</measure>
    <time_frame>15 minutes after surgery</time_frame>
    <description>Heart Rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics 2</measure>
    <time_frame>15 minutes after surgery</time_frame>
    <description>Blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory outcome 1</measure>
    <time_frame>15 minutes after surgery</time_frame>
    <description>Tidal Volume (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory outcome 2</measure>
    <time_frame>15 minutes after surgery</time_frame>
    <description>End Tidal Carbon Dioxide (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (&quot;Dixon's up and down&quot; method).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Remifentanil Effect site concentration</intervention_name>
    <description>After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (&quot;Dixon's up and down&quot; method).</description>
    <arm_group_label>remifentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18&lt;age&lt;67

          -  6 hrs fasting

          -  American society of anesthesiology (ASA) Physical Status I o II

          -  Informed consent

        Exclusion Criteria:

          -  Absence of inclusion criteria

          -  Use of cough suppressors, angiotensin converting enzyme-inhibitors, sedatives 4 weeks
             before surgery

          -  Arhythmia, pacemaker or unstable cardiovascular disease

          -  Hepatic or renal failure

          -  Anticipated difficulty in airways management

          -  Chronic obstructive pulmonary disease (COPD), Asthma, increased risk for inhalation,
             airway infection in the previous 4 weeks;

          -  Smoker

          -  Obesity (BMI &gt;35)

          -  Pregnancy

          -  Hypersensitivity to drugs administered for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Finco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cagliari University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Onida, MD</last_name>
    <phone>+39 07051096543</phone>
    <email>paolo.onida80@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Mura, MD</last_name>
    <phone>+39 07051096543</phone>
    <email>mura_paolo@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Duilio Casula</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09072</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Prof. Gabriele Finco</investigator_full_name>
    <investigator_title>Professor of Anesthesiology and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Thyroidectomy</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Extubation</keyword>
  <keyword>Cough</keyword>
  <keyword>Target controlled infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

